---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044741"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:59:10.582437+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncocyte reports Q3 loss of $13.5M; GraftAssure signed 2% US, 9% German transplant volumes

## Summary
- Q3 revenue $115K from pharma services; loss from operations $13.5M ($0.98/sh); non-GAAP loss $5.6M.
- Cash end Q3 $5.1M; raised $10.2M gross ($9.4M net) in Oct. private placement at $2.948/sh, 3.46M shares.
- GraftAssure signed centers: ~9% German, ~2% US transplant volumes; on track for 20 centers by end of 2025.
- FDA pre-sub (Q-sub) submitted for VitaGraft+ IVD; meeting scheduled early Dec.; six hospitals interested in clinical study.
- Operating expenses (excl. non-cash) rose ~13% sequentially to $13.6M, driven by R&D and sales/marketing.

## SEC filing metadata
- accession: 0001493152-24-044741
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224044741/0001493152-24-044741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224044741/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044741
- JSON: https://secwatch.observer/filing/0001493152-24-044741.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.